Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

This report summarizes updated recommendations for managing the drug-drug interactions that occur when using antiretroviral therapy during TB treatment. Changes from previous versions of these guidelines include an effort to obtain and summarize the clinical experience of using specific antiretroviral regimens during TB treatment (not just pharmacokinetic data), a table summarizing the clinical experience with key antiretroviral regimens and providing recommended regimens (Table 1), and sections on treatment for special populations (young children, pregnant women, patients with drug-resistant TB). Drug-drug interaction data are included for antiretroviral drugs that have been approved or are currently available through expanded access programs in the United States.